Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial
fibrillation patients with severe renal impairment, compared with DU-176b administered to
non-valvular atrial fibrillation (NVAF) patients with normal renal function or mild renal
impairment (Normal/MiRI).